IQVIA Holdings Inc. (NYSE:IQV) Holdings Lowered by Boston Partners

Boston Partners lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 99.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,348 shares of the medical research company's stock after selling 451,003 shares during the quarter. Boston Partners' holdings in IQVIA were worth $775,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wealthfront Advisers LLC grew its stake in IQVIA by 8.8% during the 3rd quarter. Wealthfront Advisers LLC now owns 5,389 shares of the medical research company's stock valued at $1,060,000 after acquiring an additional 438 shares in the last quarter. Knights of Columbus Asset Advisors LLC boosted its holdings in shares of IQVIA by 4.4% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 3,548 shares of the medical research company's stock worth $698,000 after purchasing an additional 149 shares during the last quarter. Empirical Finance LLC increased its holdings in shares of IQVIA by 10.9% in the third quarter. Empirical Finance LLC now owns 6,407 shares of the medical research company's stock valued at $1,261,000 after purchasing an additional 629 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in IQVIA by 6.0% during the third quarter. Coldstream Capital Management Inc. now owns 3,021 shares of the medical research company's stock worth $594,000 after buying an additional 170 shares in the last quarter. Finally, Duality Advisers LP acquired a new position in IQVIA during the third quarter worth $491,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Truist Financial cut their target price on IQVIA from $297.00 to $292.00 and set a "buy" rating for the company in a research note on Friday, May 3rd. BTIG Research began coverage on shares of IQVIA in a report on Tuesday, February 13th. They issued a "buy" rating and a $285.00 target price on the stock. Guggenheim downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. StockNews.com upgraded IQVIA from a "hold" rating to a "buy" rating in a report on Friday, February 16th. Finally, SVB Leerink started coverage on IQVIA in a research note on Monday, February 26th. They set an "outperform" rating and a $290.00 target price for the company. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $257.57.

Insider Transactions at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares of the company's stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Trading Down 1.6 %

NYSE:IQV traded down $3.82 on Friday, reaching $231.18. 723,943 shares of the company's stock were exchanged, compared to its average volume of 932,073. The business has a fifty day moving average of $239.90 and a 200-day moving average of $227.83. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The firm has a market capitalization of $42.12 billion, a price-to-earnings ratio of 31.58, a price-to-earnings-growth ratio of 2.32 and a beta of 1.52.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The firm's revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.54 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.1 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.